07 Apr COGNITE Trial: The Effectiveness of Two Common Medications on Early Stage Alzheimer’s Disease
WHAT IS THE PURPOSE OF THIS STUDY?
To measure the effectiveness of ibuprofin and chromalyn sodium on progression of early stage Alzheimer’s disease.
WHO IS ELIGIBLE?
Individuals who are between 55 and 79 years of age, have at least 8 years of education, have noticed changes in memory or normal everyday behavior, and be in good general health.
WHAT DO THEY NEED TO DO?
1.Visit http://cognitetrial.com for more information.
2. Call the Integrace Institute at 410-552-3218 to schedule an informational visit with a care partner.
3. Participate in up to 5 visits consisting of cognitive testing and study-related procedures.
WHO IS CONDUCTING THIS STUDY?
A company called ALZTherapies is conducting the study in partnership with the Integrace Institute and the Samuel & Alexia Bratton Memory Clinic.